论文部分内容阅读
目的观察1,25(OH)_2VitD_3对阿霉素肾病大鼠的保护作用。方法将雄性SD大鼠随机分为正常组、模型组、药物组和阳性对照组,每组10只。模型组、药物组和阳性对照组大鼠尾静脉注射阿霉素制造慢性肾病模型。药物组和阳性对照组大鼠分别用5μg/(kg·d)~(-1)的1,25(OH)_2VitD_3和4 mg/(kg·d)~(-1)的贝那普利灌胃,正常组和模型组给予等量花生油灌胃。8周后检测大鼠24 h尿蛋白定量、血清尿素氮(blood urea nitrogen,BUN)、血肌酐(creatinine,Scr)、总蛋白(plasma total protein,TP)、白蛋白(serum albumin,ALB)、胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)的含量。统计采用单因素方差分析,组内比较采用LSD-t进行分析,以P<0.05为差异有统计学意义。结果模型组大鼠尿蛋白、BUN、Scr、TG、TC含量分别(106.9±7.19)mg/24 h、(41.73±4.26)mmol/L、(141.13±8.04)μmol/L、(3.27±0.15)、(9.41±0.33)mmol/L,较正常组的(10.9±4.22)mg/24 h、(8.58±3.55)mmol/L、(53.33±7.67)μmol/L、(0.37±0.14)、(1.46±0.24)mmol/L明显增多,差异均有统计学意义(均P<0.05),而TP、ALB含量分别为(42.80±4.74)、(19.36±2.44)g/L,较正常组的(74.48±2.68)、(34.27±2.00)g/L显著降低,差异均有统计学意义(均P<0.05)。药物组和阳性对照组干预治疗后,尿蛋白、BUN、Scr、TG、TC含量分别为(53.8±6.64)mg/24 h、(20.74±4.17)mmol/L、(77.58±7.94)μmol/L、(0.65±0.10)、(2.79±0.38)mmol/L和(56.8±4.59)mg/24 h、(23.12±4.65)mmol/L、(84.55±7.56)μmol/L、(0.75±0.21)、(3.08±0.46)mmol/L,较模型组明显降低,差异均有统计学意义(均P<0.05),而TP、ALB含量分别为(54.08±3.47)、(25.13±1.83)g/L和(49.15±4.36)、(23.51±1.82)g/L,含量显著增加,差异均有统计学意义(P<0.05)。结论 1,25(OH)_2VitD_3能减少尿蛋白的排出,提高血浆蛋白的含量,改善脂类代谢,对肾脏具有保护作用。
Objective To observe the protective effect of 1,25 (OH) _2VitD_3 on doxorubicin nephropathy rats. Methods Male SD rats were randomly divided into normal group, model group, drug group and positive control group, with 10 rats in each group. The model group, the drug group and the positive control group were injected with doxorubicin into the caudal vein to make chronic nephropathy model. The rats in the drug group and the positive control group were treated with benazepril irrigation with 1,25 (OH) 2VitD_3 and 4 mg / (kg · d) -1 at 5 μg / kg · d -1, respectively Stomach, normal group and model group were given equal amount of peanut oil gavage. After 8 weeks, 24 h urinary protein, serum urea nitrogen (BUN), creatinine (Scr), total protein (TP), serum albumin (ALB) Total cholesterol (TC), triglycerides (TG) were measured. Statistical analysis using one-way analysis of variance, the group compared using LSD-t analysis, P <0.05 was considered statistically significant. Results The levels of urinary protein, BUN, Scr, TG and TC in the model group were (106.9 ± 7.19) mg / 24 h and (41.73 ± 4.26) mmol / L and (141.13 ± 8.04) μmol / L and , (9.41 ± 0.33) mmol / L, respectively, which was significantly higher than that of the normal group (10.9 ± 4.22 mg / 24h, (8.58 ± 3.55) mmol / L, (53.33 ± 7.67) μmol / L, (0.37 ± 0.14) ± 0.24) mmol / L, the differences were statistically significant (P <0.05), while the levels of TP and ALB were (42.80 ± 4.74) and (19.36 ± 2.44) g / L, respectively, ± 2.68) and (34.27 ± 2.00) g / L, respectively, with significant difference (all P <0.05). The levels of urinary protein, BUN, Scr, TG and TC were (53.8 ± 6.64) mg / 24 h, (20.74 ± 4.17) mmol / L and (77.58 ± 7.94) μmol / L respectively after intervention in the drug group and the positive control group , (0.65 ± 0.10), (2.79 ± 0.38) mmol / L and (56.8 ± 4.59) mg / 24 h, respectively (3.08 ± 0.46) mmol / L, which were significantly lower than those in model group (all P <0.05), while the contents of TP and ALB were (54.08 ± 3.47), (25.13 ± 1.83) g / (49.15 ± 4.36) and (23.51 ± 1.82) g / L, respectively, and the difference was statistically significant (P <0.05). Conclusion 1,25 (OH) _2VitD_3 can reduce urinary protein excretion, increase plasma protein content, improve lipid metabolism, and have a protective effect on the kidney.